Hagens Berman Launches Securities Fraud Probe into Aardvark Therapeutics Following ARD-101 Clinical Hold
AARD sits 30% above its 52-week low of $3.35.
Summary
Hagens Berman has initiated a securities fraud investigation into Aardvark Therapeutics, focusing on the company's disclosures regarding the safety and efficacy of its lead drug candidate, ARD-101, and its communications with the FDA. This probe follows the company's announcement in late February and March of a voluntary pause in the Phase 3 HERO trial for ARD-101 due to cardiac observations, which caused a 56% stock decline. The situation escalated with the FDA placing a full clinical hold on ARD-101 on May 14. This legal action adds significant financial and reputational risk to Aardvark, compounding the challenges from the halted development of its primary asset.
At the time of this announcement, AARD was trading at $4.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $93.6M. The 52-week trading range was $3.35 to $17.94. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: PR Newswire.